BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35676787)

  • 1. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4
    Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X
    Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNFR2-expressing CD4
    He J; Li R; Chen Y; Hu Y; Chen X
    Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4
    He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X
    Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distepharinamide, a novel dimeric proaporphine alkaloid from Diploclisia glaucescens, inhibits the differentiation and proliferative expansion of CD4
    Chen FY; Geng CA; Chou CK; Zheng JB; Yang Y; Wang YF; Li TZ; Li P; Chen JJ; Chen X
    Phytomedicine; 2022 Dec; 107():154482. PubMed ID: 36202057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer.
    Nie Y; He J; Shirota H; Trivett AL; Yang D; Klinman DM; Oppenheim JJ; Chen X
    Sci Signal; 2018 Jan; 11(511):. PubMed ID: 29295954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
    Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
    Front Immunol; 2018; 9():583. PubMed ID: 29623079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
    Chen Y; Jia M; Wang S; Xu S; He N
    Front Immunol; 2022; 13():835690. PubMed ID: 35251028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment.
    Chen X; Wu X; Zhou Q; Howard OM; Netea MG; Oppenheim JJ
    J Immunol; 2013 Feb; 190(3):1076-84. PubMed ID: 23277487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paeoniflorin ameliorates murine lupus nephritis by increasing CD4
    Liang CL; Lu W; Qiu F; Li D; Liu H; Zheng F; Zhang Q; Chen Y; Lu C; Li B; Dai Z
    Biochem Pharmacol; 2021 Mar; 185():114434. PubMed ID: 33513343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro generated Th17 cells support the expansion and phenotypic stability of CD4(+)Foxp3(+) regulatory T cells in vivo.
    Zhou Q; Hu Y; Howard OM; Oppenheim JJ; Chen X
    Cytokine; 2014 Jan; 65(1):56-64. PubMed ID: 24080164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signaling pathway(s) of TNFR2 required for the immunoregulatory effect of CD4
    He T; Zhao Y; Zhao P; Zhao L; Zakaria J; Wang K
    Int Immunopharmacol; 2022 Jul; 108():108823. PubMed ID: 35623290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progranulin promotes tumour necrosis factor-induced proliferation of suppressive mouse CD4⁺ Foxp3⁺ regulatory T cells.
    Hu Y; Xiao H; Shi T; Oppenheim JJ; Chen X
    Immunology; 2014 Jun; 142(2):193-201. PubMed ID: 24383743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
    Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells.
    Chen X; Hamano R; Subleski JJ; Hurwitz AA; Howard OM; Oppenheim JJ
    J Immunol; 2010 Jul; 185(1):174-82. PubMed ID: 20525892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4
    Ghods A; Mehdipour F; Shariat M; Talei AR; Ghaderi A
    Mol Immunol; 2021 Sep; 137():52-56. PubMed ID: 34214829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferential Expansion of CD4
    Chou CK; Chen X
    Methods Mol Biol; 2020; 2111():71-78. PubMed ID: 31933199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4
    He T; Liu S; Chen S; Ye J; Wu X; Bian Z; Chen X
    Front Immunol; 2018; 9():1556. PubMed ID: 30038619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical Application of Tetrandrine Nanoemulsion Promotes the Expansion of CD4
    Chen S; Lin Z; He T; Islam MS; Xi L; Liao P; Yang Y; Zheng Y; Chen X
    Front Immunol; 2022; 13():800283. PubMed ID: 35464441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF-TNFR2 Signal Plays a Decisive Role in the Activation of CD4
    Islam MS; Yang Y; Chen X
    Adv Exp Med Biol; 2021; 1278():257-272. PubMed ID: 33523452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
    Zou H; Li R; Hu H; Hu Y; Chen X
    Front Immunol; 2018; 9():594. PubMed ID: 29632537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.